ÂÜÀòÂÒÂ×

Dr. Freedland is a Partner at Samsara, which he joined in 2017. Previously, he was a Principal at Sofinnova Ventures where he played a central role in Sofinnova’s investments in BioClin Therapeutics, Civitas (acquired by Acorda), NextCure, NuCana Biomed, Principia Biopharma, Spark Therapeutics, Ziarco (acquired by Novartis), and ZS Pharma (acquired by AstraZeneca). Before his transition to healthcare investing, Dr. Freedland was a Vice President in the healthcare investment banking practice at Morgan Stanley where he advised on more than $12B of strategic and financing transactions in the biopharmaceutical and life science tools/diagnostics sectors. He holds a PhD in Pharmacology from Wake Forest University School of Medicine, an MBA from the Kellogg School of Management, and a BA in Psychology and Religious Studies from Connecticut College.